Q-omics provides the consensus-scored GLIS1 profile across patient tissues and cancer cell-line models. GLIS1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GLIS1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, GLIS1 RNA expression shows 13,215 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where GLIS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLIS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLIS1 survival associations across molecular data types. GLIS1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLIS1 RNA expression–survival associations across cancer types. High GLIS1 expression shows unfavorable associations in ACC, BLCA, LIHC and SKCM, but favorable associations in LGG and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GLIS1 RNA expression.
This table summarizes GLIS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GLIS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLIS1 shows lower tumor expression in KICH and BLCA and higher tumor expression in KIRC, HNSC, LUSC and LUAD. The KIRC box plot shows higher GLIS1 RNA expression in tumor versus normal tissue (log2 FC = +2.123, t-test p < 0.001).
This table shows molecular features associated with GLIS1 in patient tissues and cancer cell lines. In patient samples, GLIS1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GLIS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
